"The Coronavirus Immunotherapeutic Consortium (CoVIC) is an international effort to conduct side-by-side comparisons of therapeutic antibody candidates against SARS-CoV-2 spike originating from multiple sources, such as COVID-19 survivors and in silico design. 
Covered in this webinar:
Analysis by seven partner labs of antibody features including in vivo protection, spike protein affinity, epitope binning, blockage of ACE-2 binding, neutralization of pseudovirus and authentic virus infection, risk of mutagenic escape, and Fc-mediated functions. 
A publicly available database (CoVIC-DB) that allows analysis of relationships among antibody features and can inform selection of potent antibody therapies that are resistant to viral mutagenic escape.   

"